arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Edwards Lifesciences Corp

EW
$100.81 ▲ +1.55 (+1.57%) at close
Healthcare ·Orthopedic, Prosthetic & Surgical Appliances & Supplies ·USOrthopedic, Prosthetic & Surgical Appliances & Supplies
72 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
78
Health
Good
Bullish
auto_awesome

Analytical Summary

Edwards Lifesciences Corp shows strong fundamentals with top-quartile Profit Margin (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $58.1B
Dividend Yield —
Revenue Growth 13.6% ↘
Op. Margin 29.5% →
ROIC 2.1% ↘
FCF / Share $1.01 ↗
Trailing P/E 240.0x
Price / Book 5.5x
FCF Yield 1.0%
Debt / Equity 0.06
info Valuation on last close. End-of-day price, Nov 5, 2026.

72-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.74B
↑ +13.6% —
Net Income Profit after all expenses
$241.90M
↓ -27.4% —
Operating Margin Operating profit as % of sales
29.5%
↑ +1.8% 77th
FCF / Share Free cash flow per share
$1.01
↑ +2886.0% —
Long-Term Debt Long-term obligations
$598.70M
— 0.0% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↓
80
Returns ↓
69
Financial Health ↓
90
Cash Quality ↑
74

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 19 years · 72 quarters